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Norovirus is the most common cause of sporadic gastroenteritis and outbreaks worldwide. The rapid identification of norovirus
has important implications for infection preventionmeasures andmay reduce the need for additional diagnostic testing. The
Xpert Norovirus assay recently received FDA clearance for the detection and differentiation of norovirus genogroups I and II (GI
and GII), which account for the vast majority of infections. In this study, we evaluated the performance of the Xpert Norovirus
assay with both fresh, prospectively collected (n 914) and frozen, archived (n 489) fecal specimens. A Centers for Disease
Control and Prevention (CDC) composite reference method was used as the gold standard for comparison. For both prospective
and frozen specimens, the Xpert Norovirus assay showed positive percent agreement (PPA) and negative percent agreement
(NPA) values of 98.3% and 98.1% for GI and of 99.4% and 98.2% for GII, respectively. Norovirus prevalence in the prospective
specimens (collected fromMarch toMay of 2014) was 9.9% (n 90), with the majority of positives caused by genogroup II (82%,
n 74). The positive predictive value (PPV) of the Xpert Norovirus assay was 75% for GI-positive specimens, whereas it was
86.5% for GII-positive specimens. The negative predictive values (NPV) for GI and GII were 100% and 99.9%, respectively.
Globally, norovirus is the most common cause of endemic andepidemic gastroenteritis in all age groups (1). Within the
United States, it is estimated that norovirus infections account for
400,000 emergency room visits, 56,000 to 71,000 hospitalizations,
and 570 to 800 deaths annually (2). In countries that have imple-
mented rotavirus vaccination programs, norovirus has become
the leading cause of gastroenteritis in young children, in both
outpatient and hospitalized individuals (3–6).
Norovirus, originally called Norwalk virus, was identified from
a gastroenteritis outbreak in Norwalk, OH, when the viral parti-
cles were visualized using electron microscopy (7). Genomic se-
quence data place norovirus in the genus Norovirus in the family
Caliciviridae, which also includes Sapovirus, Lagovirus, Nebovirus,
and Vesivirus, which are all small, nonenveloped, positive-sense
RNA viruses. Currently, there are 7 known genogroups of noro-
virus, designated genogroup I (GI) to GVII, and over 40 genotypes
(8). The majority of norovirus infections in humans are caused by
GI and GII viruses (9). Norovirus can be transmitted via the fecal-
oral route, through aerosolization of viral particles in vomitus (10,
11), and through contaminated food, water, and environmental
sources (12).
Norovirus infections are characterized by a variety of symp-
toms, including vomiting, nonbloody diarrhea, abdominal pain,
nausea, and a low-grade fever. In otherwise healthy individuals,
norovirus infections are typically self-limiting and resolve within a
few days of symptom onset. However, norovirus symptoms can be
more severe and prolonged in the elderly, young children, and
immunocompromised individuals. Currently, there are no U.S.
Food and Drug Administration (FDA)-approved treatments or
vaccines for norovirus infections, so treatment is chiefly support-
ive care, such as rehydration.
Laboratory methods for norovirus detection have evolved over
time. Although both feces and vomitus may be analyzed, feces is
usually regarded as the specimen of choice because of the higher
viral load in this specimen type. Electron microscopy was histor-
ically used to diagnose norovirus infection, but it is costly, time-
consuming, and not readily available in many hospitals and is thus
not used routinely in most clinical laboratories today. Norovirus
cannot be isolated in routine cell cultures in the laboratory.
Enzyme immunoassays have been developed for detecting no-
rovirus GI and GII antigens in fecal specimens, but these assays
have differing sensitivities (31% to 92%) and specificities (65.3%
to 100%) (summarized in reference 13). Variability in the noro-
virus burden in fecal specimens and variability in the viral geno-
type are factors that influence the performance characteristics of
the antigen assays. One antigen assay, the Ridascreen norovirus
test (R-Biopharm, Darmstadt, Germany), has been cleared by the
FDA, but only for investigation of norovirus outbreaks (rather
than for diagnosing disease in individual patients).
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Although no specific antimicrobial therapy is used to treat no-
rovirus infection, a rapid and accurate diagnosis can expedite ap-
propriate infection prevention measures and reduce the necessity
of additional diagnostic procedures and can also facilitate public
health measures if the infection is part of an outbreak. Nucleic acid
amplification tests (NAATs) for norovirus detection have gone
through several iterations and have now become the mainstay for
identification of norovirus in clinical specimens. Several commer-
cial multiplex NAAT gastrointestinal pathogen panels which in-
clude norovirus as a target have received FDA clearance. These
assays include the xTAG Gastrointestinal Pathogen Panel (GPP)
(Luminex, Austin, TX), the FilmArray Gastrointestinal (GI) Panel
(Biofire, Salt Lake City, UT), and the Verigene Enteric Pathogens
Nucleic Acid test (Nanosphere, Northbrook, IL) (14–18). The
Xpert Norovirus assay, which is easy to perform, can be run on
demand, and has a short (90-min) turnaround time, recently
received FDA clearance and is the first standalone molecular assay
for detection of norovirus. The objective of this multicenter study
was to evaluate the laboratory and clinical performance character-
istics of the Xpert Norovirus assay.
MATERIALS AND METHODS
Specimens. This study evaluated both prospectively collected, fresh spec-
imens (collected from March to May 2014) and banked, frozen specimens
(collected from January 2008 to May 2014). At each study site, specimens
were deidentified by a third-party individual who documented basic in-
formation, including patient age, gender, and health care setting. Fresh
and frozen unpreserved and unformed fecal specimens were included in
the study if they were collected from patients presenting with acute gas-
troenteritis, if a sufficient amount was available both for Xpert Norovirus
assay testing and for the composite reference method, and if the Xpert
Norovirus assay could be performed within 24 h of collection for fresh
specimens or within 24 h of thawing for frozen specimens. Frozen speci-
mens also had to be stored at70°C prior to testing. A total of 914 fresh
fecal specimens were collected and tested at 6 clinical trial sites, while 489
frozen fecal specimens were tested at 7 clinical trial sites (Table 1). Insti-
tutional review board (IRB)/ethics committee approval was obtained at
each study site.
Xpert Norovirus assay. The Xpert Norovirus assay was performed
according to the manufacturer’s instructions. Briefly, a swab was placed
into the fecal specimen to gather a small amount of material, and then the
swab was inserted, broken off, and left in a sample reagent vial. The sample
reagent vial with the swab tip was then subjected to vortex mixing for 10 s.
This entire mixture was transferred, using a disposable pipette, into the
sample chamber of an Xpert Norovirus assay cartridge and loaded on a
GeneXpert instrument system platform for testing. If an indeterminate
result (an invalid result, an error, or no result) was obtained, then the
specimen was tested one additional time. Each day of testing, one negative
and two positive controls, including separate GI and GII positive controls,
were tested and had to be acceptable prior to testing patient specimens.
Xpert Norovirus assay cartridges contain a sample processing control
(SPC) and a probe check control (PCC). The SPC controls for adequate
specimen processing and the presence of PCR inhibitors, while the PCC
controls for reagent rehydration, PCR tube filling within the cartridge,
probe integrity, and dye stability. All controls had to perform as expected
in all cases for the assay result to be considered valid. After Xpert Norovi-
rus assay testing, all specimens were stored at70°C prior to shipment
on dry ice to the CDC for composite reference method testing.
Composite reference method. As a gold standard for comparison, a
composite reference method was used at the CDC. The composite refer-
ence method consisted of a real-time reverse transcription (RT)-PCR as-
say (19) with modifications and a conventional RT-PCR that amplified
two distinct regions of the capsid gene (termed regions C and D) followed
by bidirectional sequencing (19). The primers used in the composite
method were different from the ones used in the Xpert Norovirus assay.
The algorithm for the composite method result interpretation is shown in
Table 2. Norovirus-positive samples were genotyped by comparisons with
reference sequences (9). Testing at the CDC was performed on specimens
in batches.
Statistical analysis. A power calculation was performed to determine
the requirements for the study to demonstrate that the lower 2-sided 95%
confidence interval for positive percent agreement (PPA) was greater than
85% and that the lower 2-sided 95% confidence interval for negative
percent agreement (NPA) was greater than 82%. In order to ensure a
reasonable probability of meeting the significance criteria, the PPA and
NPA targets were 95% and 92%, respectively. Thus, the sample size re-
quirements included a minimum of 124 samples positive for each of GI
and GII norovirus and 155 negative specimens. The positive percent
agreement (PPA), negative percent agreement (NPA), positive predictive
value (PPV), and negative predictive value (NPV) were calculated using
standard methods. The 95% confidence interval was calculated using a
two-tailed Fisher’s exact method.
RESULTS
Specimens. A total of 1,413 eligible fecal specimens were col-
lected for Xpert Norovirus assay testing. Ten specimens (5 with
indeterminate results from the composite reference method, 4
that were not tested within 24 h of collection, and 1 with an
indeterminate result by the Xpert Norovirus assay) were ex-
cluded from the final analysis, resulting in a total of 1,403 spec-
imens for analysis (Fig. 1). Of the 1,403 specimens analyzed,
914 were fresh specimens (collected from March to May 2014)
and 489 were frozen specimens. The frozen specimens were
preselected to increase the number of GI-positive specimens.
Two frozen specimens were excluded from the GII analysis due
to indeterminate Xpert Norovirus assay results, resulting in
1,401 specimens analyzed for GII results (Fig. 1).
TABLE 1 Number of fresh and frozen specimens tested at each clinical
site
Study site
No. of specimens tested
Fresh Frozen Total
A 119 29 148
B 307 28 335
C 383 38 421
D 38 219 257
E 57 32 89
F 0 32 32
G 10 111 121
Total 914 489 1,403
TABLE 2 Composite reference test algorithm for result interpretation
CDC norovirus
real-time RT-
PCR result
Result from CDC
conventional
RT-PCR (region
C) with BDSa
Result from CDC
conventional
RT-PCR (region
D) with BDS
Gold standard
result
Positive Positive NAb Positive
Negative Positive NA Positive
Positive Negative Positive Positive
Positive Negative Negative Negative
Negative Negative NA Negative
a BDS, bidirectional sequencing.
b NA, not applicable.
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Study subjects. The numbers of subjects were approximately
equal with regard to gender distribution (females, n  738,
52.6%) (Table 3). Nearly half (n 675, 48.1%) of all subjects were
between 21 to 65 years of age, and over one-third (n 531, 37.8%)
of the subjects were 65 years of age (Table 3). The majority of
specimens came from subjects who were hospitalized (n  907,
64.6%), with outpatients being the next-most-common patient
population (n 272, 19.4%) (Table 3).
XpertNorovirus assay performance.The Xpert Norovirus as-
say provided a valid result for 98.6% (1,383/1,403) of the speci-
mens in the first attempt at analysis, with the analyses of 20 (1.4%)
specimens showing indeterminate results. Repeat testing resulted
in a valid assay result for all 20 repeat specimens. Of the 1,403
specimens tested, 23.7% (n 333) were positive for GI or GII by
the Xpert Norovirus assay (Table 4). Of the norovirus-positive
specimens, 41.4% (n  138) were GI and 58.6% (n  195) were
GII. No dually GI-positive and GII-positive specimens were de-
tected by the Xpert Norovirus assay.
As there is no established gold standard for norovirus testing,
the results from the Xpert Norovirus assay were compared to the
results from the composite reference testing that was conducted at
the CDC. On the basis of the composite method, the Xpert Noro-
virus assay positive percent agreement (PPA) and negative percent
agreement (NPA) for all specimens were 98.3% and 98.1% for
GI-positive specimens and 99.4% and 98.2% for GII-positive
specimens, respectively (Table 5). The positive predictive value
(PPV) and negative predictive value (NPV) for fresh specimens
were 75.0% and 100% for GI-positive specimens and 86.5% and
99.9% for GII-positive specimens, respectively (Table 5).
Analysis of prospective specimens. The fresh prospectively
collected specimens were obtained from the clinical trial sites
from March to May of 2014, and over this time period 9.9% (n
90) of specimens tested positive for norovirus by the Xpert Noro-
virus assay (Table 6). Of these positive specimens, 17.8% (n 16)
were GI and 82.2% (n 74) GII. Most of the positive specimens
were submitted from hospitalized subjects (38.9%), followed by
outpatients (27.8%) and patients in long-term-care facilities
(25.6%). Finally, while 27.7% (n  253) of specimens were col-
lected in March, that month accounted for 53.3% (n 48) of all
norovirus-positive specimens (Table 6).
Norovirus genotypes.A sequence that could be genotyped was
obtained from each the 286 Xpert Norovirus assay-positive sam-
ples. The genotypes that were detected by the Xpert Norovirus
assay included GI.1 (n 1), GI.3 (n 3), GI.3B (n 23), GI.3C
(n 16), GI.4 (n 14), GI.5 (n 1), GI.5A (n 3), GI.6 (n 1),
GI.6A (n 28), GI.7 (n 22), GI.9 (n 1), GII.1 (n 3), GII.2
(n 4), GII.3 (n 5), GII.4 New Orleans (n 74), GII.4 Osaka
(n  1), GII.4 Sydney (n  75), GII.6 (n  2), GII.6B (n  1),
GII.13 (n 7), and GII.14 (n 1).
DISCUSSION
Norovirus can cause both sporadic gastroenteritis and outbreaks;
norovirus outbreaks are associated with health care institutions,
cruise ships, schools, and other environments in which people are
in close quarters. A meta-analysis of acute gastroenteritis cases
worldwide revealed that norovirus accounts for 18% of all diar-
FIG 1 Overview of specimens collected and tested by the Xpert Norovirus
assay. Of the 6 specimens that were excluded for indeterminate results, 5 were
indeterminate by the composite reference method and 1 was indeterminate by
the Xpert Norovirus assay. The true-positive (TP), true-negative (TN), false-
positive (FP), and false-negative (FN) results of the Xpert Norovirus assay
were determined by the composite reference method.
TABLE 3 Demographics of study subjects
Subject parameter
No. (%) of specimens
Fresha Frozenb All
Gender
Male 420 (46.0) 225 (46.0) 645 (46.0)
Female 494 (54.0) 244 (49.9) 738 (52.6)
Not specified 0 (0.0) 20 (4.1) 20 (1.4)
Age range (yrs)
0–1 8 (0.8) 12 (2.4) 20 (1.4)
1–5 6 (0.7) 46 (9.4) 52 (3.7)
5–12 10 (1.1) 35 (7.2) 45 (3.2)
12–21 29 (3.2) 32 (6.5) 61 (4.4)
21–65 520 (56.9) 155 (31.7) 675 (48.1)
65 341 (37.3) 190 (38.9) 531 (37.8)
Not specified 0 (0.0) 19 (3.9) 19 (1.4)
Health care setting
Emergency department 48 (5.2) 13 (2.6) 61 (4.3)
Hospitalized 561 (61.4) 346 (70.8) 907 (64.6)
LTCFc 81 (8.9) 0 14 (2.9) 95 (6.8)
Outpatient 223 (24.4) 49 (10) 272 (19.4)
Other 1 (1.1) 67 (13.7) 68 (4.9)
a Data represent percentages of all fresh specimens (n 914).
b Data represent percentages of all frozen specimens (n 489).
c LTCF, long-term-care facility.
TABLE 4 Xpert Norovirus assay-positive specimens by norovirus
genogroup
Norovirus
genogroup
No. (%) of specimens
Fresha Frozenb All
GI 16 (1.8) 122 (25) 138 (9.8)
GII 74 (8.1) 121 (24.7) 195 (13.9)
Negative 824 (90.1) 246 (50.3) 1,070 (76.3)
a Data represent percentages of all fresh specimens (n 914).
b Data represent percentages of all frozen specimens (n 489).
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rheal infections (1). On the basis of the Xpert Norovirus assay, we
observed that 9.9% (n 90) of freshly collected specimens tested
positive for norovirus. Given that 78.9% of norovirus cases in the
Northern Hemisphere occur between October and March (1), our
lower prevalence could reflect the limited time frame (i.e., March
to May of 2014) within which fresh specimens were collected. In
fact, over half (n 48, 53.3%) of the positive norovirus specimens
reported here were from March, with 70.8% (n  34) of these
specimens from a single clinical site. We also observed a predom-
inance (84%, n  64) of positive GII specimens in our study, a
result which has been noted in a previous study where GII viruses
accounted for62% of norovirus outbreaks (20).
Control of norovirus outbreaks is complicated by the relatively
low infectious dose (21) and by the high level of norovirus shed-
ding in vomitus (21) and feces (22). Routine norovirus prevention
and control measures utilize a combination of staff- and patient-
level strategies, including hand hygiene, assigning of patient co-
horts, use of appropriate protective equipment, and effective en-
vironmental disinfection (23, 24). The implementation of such
measures requires the prompt identification of norovirus-infected
patients. Among the strengths of the Xpert Norovirus assay are the
relative ease of performing the test, the ability to run samples on
demand without batch processing, and the short turnaround
time, which includes less than 5 min of hands-on time and ap-
proximately 90 min for a result.
In a study in Hong Kong, the investigators enhanced their stan-
dard infection control measures by performing norovirus PCR
testing on all specimens submitted for fecal studies, even if noro-
virus testing was not requested (25). By the use of a laboratory-
developed PCR assay for norovirus detection (26), 242 (25%) pa-
tients tested positive for norovirus; among them, 114 (47% of
positives) were detected only by testing samples for which noro-
virus testing had not been ordered. The resulting increased detec-
tion led to additional patients being identified and given proper
precautions. Overall, the authors found that these enhanced mea-
sures reduced the number of hospital-acquired norovirus infec-
tions from 131 to 16 cases per 1,000 potentially infectious patient-
days, relative to the previous 12 months (25).
Asymptomatic carriage of norovirus is an area of unknown
significance for infection prevention measures and poses a diag-
nostic problem for laboratory testing. Real-time RT-PCR testing
of fecal specimens of asymptomatic individuals in England re-
vealed a 12% age-adjusted prevalence of norovirus, with the high-
est prevalence noted for children5 years of age (27). One source
of asymptomatic shedding can be a recently resolved infection. A
median of 29 days of norovirus shedding has been documented via
real-time RT-PCR in norovirus-infected volunteers (21). The du-
TABLE 5 Performance of the Xpert Norovirus assay compared to the composite reference method
Specimen type Target n
No. of specimens with
indicated result
PPAe (95% CI) NPAf (95% CI) PPVg (95% CI) NPVh (95% CI)TPa FPb TNc FNd
Fresh GI 914 12 4 898 0 100.0 (73.5–100.0) 99.6 (98.9–99.9) 75.0 (47.6–92.7) 100.0 (99.6–100.0)
GII 914 64 10 839 1 98.5 (91.7–100.0) 98.8 (97.8–99.4) 86.5 (76.6–93.3) 99.9 (99.3–100.0)
Frozen GI 489 101 21 365 2 98.1 (93.2–99.8) 94.6 (91.8–96.6) NAi NA
GII 487 109 12 366 0 100.0 (96.7–100) 96.8 (94.5–98.3) NA NA
All GI 1,403 113 25 1,263 2 98.3 (93.9–99.8) 98.1 (97.1–98.7) NA NA
GII 1,401 173 22 1,205 1 99.4 (96.8–100) 98.2 (97.3–98.9) NA NA
a TP, true positive.
b FP, false positive.
c TN, true negative.
d FN, false negative.
e PPA, positive percent agreement; CI, confidence interval.
f NPA, negative percent agreement.
g PPV, positive predictive value.
h NPV, negative predictive value.
i NA, not applicable.
TABLE 6 Evaluation of fresh specimen results
Demographic
Information
No. (%) of specimensa
Total tested
(n 914) GI positive GII positive All positive
Gender
Male 420 (46) 4 (1) 28 (6.7) 32 (7.6)
Female 494 (54) 12 (2.4) 46 (9.3) 58 (11.7)
Age range (yrs)
0–1 8 (0.88) 0 (0) 0 (0) 0 (0)
1–5 6 (0.66) 1 (16.7) 0 (0) 1 (16.7)
5–12 10 (1.1) 0 (0) 1 (10) 1 (10)
12–21 29 (3.2) 0 (0) 3 (10.3) 3 (10.3)
21–65 520 (56.9) 9 (1.7) 35 (6.7) 44 (8.4)
65 341 (37.3) 6 (1.8) 35 (10.3) 41 (12)
Health care setting
Emergency department 48 (5.2) 1 (2.1) 6 (12.5) 7 (14.6)
Hospitalized 561 (61.4) 5 (0.9) 30 (5.3) 35 (6.2)
LTCF 81 (8.9) 1 (1.2) 22 (27.2)b 23 (28.4)
Outpatient 223 (24.4) 9 (4) 16 (7.2) 25 (11.2)
Other 1 (0.1) 0 (0) 0 (0) 0 (0)
Mo
March 253 (27.7) 6 (2.4) 42 (16.6) 48 (19)
April 329 (36) 6 (1.8) 21 (6.4) 27 (8.2)
May 332 (36.3) 4 (1.2) 11 (3.3) 15 (4.5)
a Data are presented as percentages of specimens for that given row.
b All specimens came from a single test site.
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ration of symptoms and norovirus shedding can be much longer
in immunocompromised patients than in healthy patients (28,
29). It remains unknown whether asymptomatic norovirus carri-
ers can serve as a reservoir for sporadic cases or outbreaks and
whether such individuals require infection prevention measures.
Additionally, given the potential for a high prevalence of asymp-
tomatic carriage, the only fecal specimens that should be tested for
norovirus are those from individuals with symptoms of gastroen-
teritis, similarly to parameters commonly established by clinical
laboratories for Clostridium difficile testing (30).
While there are several FDA-approved assays that include no-
rovirus as a target, the Xpert Norovirus assay is the first FDA-
cleared stand-alone NAAT specifically for norovirus detection.
There are currently 3 FDA-cleared multiplex assays for syndromic
testing for gastrointestinal pathogens that include norovirus as a
target—the xTAG GPP, the FilmArray GI panel, and the Verigene
enteric-pathogen nucleic acid test. The xTAG GPP method detects
15 gastrointestinal pathogens, including GI and GII norovirus.
This assay requires a separate nucleic acid extraction prior to am-
plification and target detection. In contrast, the FilmArray GI as-
say is a self-contained test that performs nucleic acid extraction,
detection, and interpretation of results for 22 gastrointestinal
pathogens, including GI and GII norovirus. While these assays
detect both GI and GII, they do not differentiate between these
genotypes. Two recent studies (14, 15) evaluated the FilmArray GI
panel, using a CDC-based assay as the reference method for no-
rovirus detection (31), and reported sensitivities of 91.7% and
94.5% and specificities of 99.5% and 98.8%, respectively. In the
paper by Khare et al., in addition to evaluating the FilmArray GI
panel, the authors reported that the sensitivity and specificity of
the xTAG GPP panel for norovirus were 100% and 90.8%, respec-
tively. Two other recent studies (16, 17) used a different reference
method (32) to evaluate the xTAG GPP panel and reported sensi-
tivities of 93.4% to 94.4% and specificities of 98.9% to 100%. The
results for the Xpert Norovirus assay presented here indicate sim-
ilar performance characteristics with the FilmArray GI and xTAG
GPP panels, but additional studies are needed to directly compare
these methods for norovirus detection. These studies and others
have evaluated coinfections detected by multiplex panels, which
have been reported at rates of 8% to 17.2% (14–18). In most of
these studies, norovirus is commonly a component of these coin-
fections. Given the high prevalence of asymptomatic norovirus
shedding, the clinical significance of norovirus detection in coin-
fections remains unclear and is an important area for future in-
vestigation.
This study had a number of strengths, including the large num-
ber (n 914) of prospectively collected specimens from patients
with acute gastroenteritis from multiple medical centers and di-
verse health care settings. Norovirus genotyping data revealed that
specimens in this study represented a variety of distinct GI (n 
11) and GII (n 10) genotypes, indicating that the Xpert Noro-
virus assay has the capacity to detect a variety of norovirus geno-
types. The inclusion of frozen specimens improved the power for
evaluating the analytical performance characteristics for geno-
group GI. The limitations of this study included a relative paucity
of specimens from subjects less than 21 years of age (n  178,
12.7% of total), the limited time frame and time of year (i.e.,
nonpeak) during which the samples were collected, and the low
number of GI-positive prospective specimens. Additionally, while
fecal specimens were submitted for routine studies, limited clini-
cal data are available to correlate the testing results with symptoms
and the presence of other pathogens in these samples.
In summary, the Xpert Norovirus assay is a rapid and accurate
method to detect and differentiate the prominent norovirus geno-
groups. Consistent with previous reports, we found that norovirus
is a frequent cause of acute gastrointestinal infections, and effi-
cient and accurate testing has the potential to rapidly identify in-
fected individuals, minimizing the need for additional diagnostic
testing and prompting infection prevention measures.
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